Skip to main content

Table 1 Baseline characteristics

From: Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study

  All patients (n = 520) HCC (n = 76) Non-HCC (n = 444) p value (HCC vs. non-HCC)
Mean age ± SD, years 60.46 ± 12.95 (24–89) 59.76 ± 11.67 (36–84) 60.58 ± 13.16 (24–89) 0.613
Sex     0.000
 Female, n (%) 219 (42) 16 (21) 203 (46)  
 Male, n (%) 301 (58) 60 (79) 241 (54)  
Mean follow-up ± SD, months 32.48 ± 23.22 39.57 ± 25.90 31.27 ± 22.54 0.004
Median follow-up (range), months 26.86 (6.18–109.48) 32.30 (6.77–104.02) 25.59 (6.18–109.48)  
Etiology, n (%)     0.000
 HBV 184 (35) 46 (61) 138 (31)  
 HCV 8 (2) 3 (4) 5 (1)  
 ALD 30 (6) 6 (8) 24 (5)  
 NAFLD 1 (0) 0 (0) 1 (0)  
 AIH 33 (6) 2 (3) 31 (7)  
 PBC 23 (4) 0 (0) 23 (5)  
 PSC 1 (0) 0 (0) 1 (0)  
 OTHER 240 (46) 19 (25) 221 (50)  
Mean BMI ± SD, kg/m2 23.27 ± 3.44 23.68 ± 3.13 23.18 ± 3.51 0.359
Mean PLT ± SD, 10E9/L 99.86 ± 69.27 87.99 ± 66.83 101.90 ± 69.55 0.106
Mean INR ± SD 1.28 ± 0.39 1.31 ± 0.23 1.27 ± 0.41 0.512
Mean PT ± SD, sec 14.96 ± 4.98 15.44 ± 2.70 14.87 ± 5.28 0.396
Mean ALT ± SD, U/L 60.49 ± 152.66 61.44 ± 161.54 60.32 ± 151.29 0.954
Mean AST ± SD, U/L 68.15 ± 124.32 65.24 ± 97.63 68.66 ± 128.45 0.826
Mean GGT ± SD, U/L 113.52 ± 141.60 89.04 ± 90.89 117.81 ± 148.37 0.107
Mean ALB ± SD, g/L 33.09 ± 6.33 33.00 ± 6.01 33.10 ± 6.39 0.897
Mean TBil ± SD, μmol/L 38.98 ± 48.44 35.24 ± 30.86 39.61 ± 50.81 0.476
Mean Cr ± SD, μmol/L 75.08 ± 54.49 73.65 ± 33.97 75.31 ± 57.16 0.816
Mean AFP ± SD, μg/L 14.38 ± 59.90 24.85 ± 51.65 12.31 ± 61.29 0.227
Mean THRI ± SD 239.17 ± 68.21 279.49 ± 57.07 232.27 ± 67.62 0.000
Mean APRI ± SD 2.40 ± 4.07 3.04 ± 7.65 2.29 ± 3.06 0.138
Mean FIB-4 ± SD 7.71 ± 6.31 8.58 ± 6.44 7.56 ± 6.28 0.197
Mean MELD ± SD 7.57 ± 5.99 7.81 ± 6.53 7.53 ± 5.90 0.731
Mean Child-Pugh Score ± SD 7.15 ± 1.74 7.28 ± 2.09 7.13 ± 1.67 0.545
  1. SD standard deviation, HBV hepatitis B virus, HCV hepatitis C virus, ALD alcohol liver disease, NAFLD non-alcoholic fatty liver disease, AIH autoimmune hepatitis, PBC primary biliary cirrhosis, PSC primary sclerosing cholangitis, BMI body mass index, PLT platelet count, PT prothrombin time, INR international normalized ratio, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT γ-glutamyl transpeptidase, ALB albumin, TBil total bilirubin, Cr creatinine, AFP alpha fetoprotein, THRI Toronto hepatocellular carcinoma risk index, APRI AST to platelet ratio index, FIB-4 Fibrosis-4 score, MELD model for end-stage liver disease